Search Results | Blood | American Society of Hematology

1-20 of 624

2 3 4 5

Sort by

Sort Order Select

Journal Articles

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Blood (2019) 134 (Supplement_1): 1709.

DOI: https://doi.org/10.1182/blood-2019-122032

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

DOI: https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

DOI: https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Jonathan Feld, MD, Francesca Schieppati, MD, Rosalie Odchimar-Reissig, RN, Erin P. Demakos, RN, Shyamala C. Navada, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4260.

DOI: https://doi.org/10.1182/blood-2019-128656

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

DOI: https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Xiaoyi Wang, MD MPH, Rong Wang, PhD, Chi Zhang, MD MPH, Amer M. Zeidan, MBBS, MHS, Nikolai A. Podoltsev, MD PhD, Scott F. Huntington, MD MPH, Steven D. Gore, MD, Amy J Davidoff, PhD MS, Xiaomei Ma, PhD

Blood (2019) 134 (Supplement_1): 4748.

DOI: https://doi.org/10.1182/blood-2019-128821

Published: 2019

Journal Articles

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Montserrat Arnan Sangerman, MD PhD, Helena Pomares, MD PhD, Esther Alonso, MD, Mercedes Galiano, Maite Encuentra, Javier Grau, MD PhD, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 4270.

DOI: https://doi.org/10.1182/blood-2019-127901

Published: 2019

Journal Articles

Hematologic Improvement-Neutrophil and -Platelet in the MEDALIST Trial: Multilineage Data from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions

Guillermo Garcia-Manero, MD, Ghulam J. Mufti, Pierre Fenaux, MD PhD, Rena Buckstein, MD FRCPC, Valeria Santini, MD, María Díez-Campelo, MD PhD, Carlo Finelli, Mario Cazzola, MD, Osman Ilhan, Mikkael A. Sekeres, MD MS, Alan F. List, MD, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Uwe Platzbecker, MD, Rami Komrokji

Blood (2019) 134 (Supplement_1): 4243.

DOI: https://doi.org/10.1182/blood-2019-123048

Published: 2019

Journal Articles

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Masayuki Shiseki, MD PhD, Mayuko Ishii, Mari Ohwashi, Kentaro Yoshinaga, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 4258.

DOI: https://doi.org/10.1182/blood-2019-124738

Published: 2019

Journal Articles

Molecular Features in the Diagnosis of Myeloid Neoplasms in Down Syndrome Patients Less Than Four Years of Age: Experience from a Single Institution

Chris Ours, MD, Fiorella Iglesias, MD, Erin Morales, MD, Luke Maese, DO, Archana M Agarwal, MD, Anupam Verma, MD

Blood (2018) 132 (Supplement 1): 5180.

DOI: https://doi.org/10.1182/blood-2018-99-120304

Published: 2018

Journal Articles

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

David P. Steensma, MD, Rami S. Komrokji, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Andrew M. Brunner, MD, Richard M. Stone, MD, John Barnard, PhD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4374.

DOI: https://doi.org/10.1182/blood-2018-99-117538

Published: 2018

Journal Articles

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Amer M. Zeidan, MBBS, MHS, Weiwei Zhu, MPH, Rong Wang, PhD, Maximilian Stahl, MD, Scott F Huntington, MDMPH, Smith Giri, MBBS, Nikolai A. Podoltsev, MD PhD, Steven D. Gore, MD, Xiaomei Ma, MD PhD, Amy J. Davidoff, PhD MS

Blood (2018) 132 (Supplement 1): 838.

DOI: https://doi.org/10.1182/blood-2018-99-116497

Published: 2018

Journal Articles

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Blood (2018) 132 (Supplement 1): 4392.

DOI: https://doi.org/10.1182/blood-2018-99-118070

Published: 2018

Journal Articles

Treatment with Decitabine Followed By Prednisone for Myelodysplatic Syndrome Concomitant with Sjogren's Syndrome

Xingfu Sun, Jianyong Li, MD, Hua Lu, MD PhD

Blood (2018) 132 (Supplement 1): 5530.

DOI: https://doi.org/10.1182/blood-2018-99-112020

Published: 2018

Journal Articles

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Laura McDonald, MB MRCPI, Peter McCarthy, MB BCh BAO, Mohammad Khan, MD, Patrick Hogan, MB BCh BAO, Eileen C. Kelleher, MD, Philip Murphy, MD, John Quinn, MD PhD, Ronan Desmond, MD, Johnny McHugh, MB, FRPATH, Melanie Strickland, BNS, Mary Cahill, MD, Su Wai Maung, MRCP, MBBS, Clodagh Keohane, MD, Desmond O'Neill, MD, Daniel Ryan, MD, Vitaliy Mykytiv, MD, Helen Enright, MD

Blood (2018) 132 (Supplement 1): 5515.

DOI: https://doi.org/10.1182/blood-2018-99-113290

Published: 2018

Journal Articles

Baseline Assessment of Patients with Newly-Diagnosed Acquired Bone Marrow Failure Enrolled in a Prospective Observational Study, "Search for Unidentified Links between PNH Clone Size and the Related Clinical Manifestations By High Precision Flow Cytometry (SUPREMACY)"

Yuji Yonemura, MD PhD, Tatsuya Kawaguchi, MD PhD, Ken Ishiyama, MD PhD, Chiharu Sugimori, MD PhD, Kohei Hosokawa, Naoshi Obara, MD PhD, Hideyoshi Noji, MD PhD, Yukari Shirasugi, MD PhD, Yasutaka Ueda, MD PhD, Hiroyuki Takamori, MD PhD, Tsutomu Shichishima, MD PhD, Shigeru Chiba, MD PhD, Haruhiko Ninomiya, MD PhD, Kiyoshi Ando, MD PhD, Jun-Ichi Nishimura, MD PhD, Yuzuru Kanakura, MD PhD, Masanori Takahashi, Shinji Nakao, MD PhD

Blood (2017) 130 (Supplement 1): 2466.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.2466.2466

Published: 2017

Journal Articles

Clinical Implication of Gene Mutations in Children Myelodysplastic Syndromes

Wenbin An, Chao Liu, Shuai Zhu, Yang Wan, Yingchi Zhang, PhD, Xiaofan Zhu, MD

Blood (2017) 130 (Supplement 1): 1688.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1688.1688

Published: 2017

Journal Articles

Diagnostic Value of Flow Cytometry Technique By European Leukemianet for Idiopathic Cytopenia of Undetermined Significance

Shumpei Uchida, MD, Osamu Imataki, MD, Hiroyuki Kubo, MD, Shigeyuki Yokokura, MD PhD, Makiko Uemura, MD, Naoshi Sugimoto, MD PhD, Norimitsu Kadowaki, MD PhD

Blood (2017) 130 (Supplement 1): 1707.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1707.1707

Published: 2017

Journal Articles

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Argiris Symeonidis, MD PhD, Alexandra Kourakli, MD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, Eleftheria Hatzimichael, Theodoros Vassilakopoulos, MDPhD, Aikaterini Palla, Vassiliki Pappa, MD, Evgenia Verigou, Zafeirios Kartasis, MD, Eirini Katodritou, Maria Pagoni, Theodora Assimakopoulou, Charalampos Pontikoglou, MD PhD, Maria Dimou, George Xanthopoulidis, Maria K. Angelopoulou, MD, Maria Kotsopoulou, Dimitra Liapi, Despina Mparmparousi, Evridiki Michali, Anna Kioumi, Nora-Athina Viniou, Achilles Anagnostopoulos, Vassiliki Labropoulou, Maria Dalekou, Michael Voulgarelis, MD PhD, Efthymia Vlachaki, Anna Christoforidou, Ioannis Adamopoulos, MD, Akrivi Kostourou, Petros Laos, Evangelos Terpos, MD PhD, Eleni Kapsali, George Vassilopoulos, MD PhD, Helen A. Papadaki, MD PhD, Panayiotis Panayiotidis, MD PhD, Athanasios Galanopoulos, MD PhD

Blood (2017) 130 (Supplement 1): 1696.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1696.1696

Published: 2017

Journal Articles

Clinical Outcomes of Decitabine Treatment for Patients with Lower-Risk Myelodysplastic Syndrome By the International Prognostic Scoring System

Ki Sun Jung, Jun Ho Jang, MD PhD, Je-Hwan Lee, MD PhD

Blood (2017) 130 (Supplement 1): 1697.

DOI: https://doi.org/10.1182/blood.V130.Suppl_1.1697.1697

Published: 2017

2 3 4 5

NARROW

PPM1D and DNMT3A Mutations in Myelodysplasia and Clonal Hematopoiesis

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

T-Cell Mediated Cytopenias in Patients with Myelodysplastic Syndromes Respond to Intravenous Immunoglobulin

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)

Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center

Prognostic Significance of Reduced BCAS4 expression in Bone Marrow Cells of Patients with Myelodysplastic Syndromes

Molecular Features in the Diagnosis of Myeloid Neoplasms in Down Syndrome Patients Less Than Four Years of Age: Experience from a Single Institution

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions

Elevated Labile Plasma Iron (LPI) Levels in Patients with Lower-Risk Myelodysplastic Syndromes (MDS) Are Associated with Decreased Quality of Life and Reduced Survival

Treatment with Decitabine Followed By Prednisone for Myelodysplatic Syndrome Concomitant with Sjogren's Syndrome

Should Myelodysplastic Syndromes in Very Old Patients be More Actively Managed? Clinical Characteristics, Management and Outcomes for Patients 85 Years and Older

Baseline Assessment of Patients with Newly-Diagnosed Acquired Bone Marrow Failure Enrolled in a Prospective Observational Study, "Search for Unidentified Links between PNH Clone Size and the Related Clinical Manifestations By High Precision Flow Cytometry (SUPREMACY)"

Clinical Implication of Gene Mutations in Children Myelodysplastic Syndromes

Diagnostic Value of Flow Cytometry Technique By European Leukemianet for Idiopathic Cytopenia of Undetermined Significance

Patients with Myelodysplastic Syndromes, Other Than Del(5)q Syndrome, Exhibiting Del(5)q Alone or Associated with One Additional Chromosomal Abnormality Have Comparable Probability and Duration of Response to Lenalidomide, with Patients Classified As Del(5)q Syndrome

Clinical Outcomes of Decitabine Treatment for Patients with Lower-Risk Myelodysplastic Syndrome By the International Prognostic Scoring System

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only